BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36034589)

  • 1. The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset.
    Calverley PMA; Papi A; Page C; Rogliani P; Dal Negro RW; Cazzola M; Cicero AF; Wedzicha JA
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1909-1920. PubMed ID: 36034589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.
    Calverley PM; Page C; Dal Negro RW; Fontana G; Cazzola M; Cicero AF; Pozzi E; Wedzicha JA
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2733-2744. PubMed ID: 31819405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.
    Dal Negro RW; Wedzicha JA; Iversen M; Fontana G; Page C; Cicero AF; Pozzi E; Calverley PMA; ;
    Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29025888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV
    Chai CS; Ng DL; Bt Mos S; Ibrahim MAB; Tan SB; Pang YK; Liam CK
    BMC Pulm Med; 2023 Apr; 23(1):150. PubMed ID: 37118725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
    Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
    Dal Negro RW; Visconti M; Turco P
    Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
    Calverley PM; Postma DS; Anzueto AR; Make BJ; Eriksson G; Peterson S; Jenkins CR
    Int J Chron Obstruct Pulmon Dis; 2016; 11():381-90. PubMed ID: 26952309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
    Herath SC; Normansell R; Maisey S; Poole P
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009764. PubMed ID: 30376188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
    Moretti M; Bottrighi P; Dallari R; Da Porto R; Dolcetti A; Grandi P; Garuti G; Guffanti E; Roversi P; De Gugliemo M; Potena A;
    Drugs Exp Clin Res; 2004; 30(4):143-52. PubMed ID: 15553660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis.
    Martin AL; Marvel J; Fahrbach K; Cadarette SM; Wilcox TK; Donohue JF
    Respir Res; 2016 Apr; 17():40. PubMed ID: 27084761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
    Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
    BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Kew KM; Mavergames C; Walters JA
    Cochrane Database Syst Rev; 2013 Oct; (10):CD010177. PubMed ID: 24127118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
    Ni H; Htet A; Moe S
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011897. PubMed ID: 28631387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
    Rutten-van Mölken MP; van Nooten FE; Lindemann M; Caeser M; Calverley PM
    Pharmacoeconomics; 2007; 25(8):695-711. PubMed ID: 17640111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial.
    Devereux G; Cotton S; Fielding S; McMeekin N; Barnes PJ; Briggs A; Burns G; Chaudhuri R; Chrystyn H; Davies L; De Soyza A; Gompertz S; Haughney J; Innes K; Kaniewska J; Lee A; Morice A; Norrie J; Sullivan A; Wilson A; Price D
    JAMA; 2018 Oct; 320(15):1548-1559. PubMed ID: 30326124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different impacts of respiratory symptoms and comorbidities on COPD-specific health-related quality of life by COPD severity.
    Lee H; Jhun BW; Cho J; Yoo KH; Lee JH; Kim DK; Lee JD; Jung KS; Lee JY; Park HY
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3301-3310. PubMed ID: 29180860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
    Janjua S; Fortescue R; Poole P
    Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.
    Tashkin DP; Rennard SI; Martin P; Ramachandran S; Martin UJ; Silkoff PE; Goldman M
    Drugs; 2008; 68(14):1975-2000. PubMed ID: 18778120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Tiotropium/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Naïve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials.
    Buhl R; de la Hoz A; Xue W; Singh D; Ferguson GT
    Adv Ther; 2020 Oct; 37(10):4175-4189. PubMed ID: 32671684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.